NephroCheck is a test that tries to determine the risk of some who is seriously sick developing acute kidney injury.[1] Whether or not the test improves outcomes, however, is unclear as of 2016.[2]
NephroCheck tests for the presence of insulin-like growth-factor binding protein 7 (IGFBP7) and tissue inhibitor of metalloproteinases (TIMP-2) in the urine, which are associated with acute kidney injury.[1] The laboratory test was developed by Astute Medical, in San Diego, California.[1]
References edit
- ^ a b c FDA. "FDA allows marketing of the first test to assess risk of developing acute kidney injury". www.fda.gov. FDA. Archived from the original on 8 February 2017. Retrieved 2014-09-05.
- ^ Lameire, N; Vanmassenhove, J; Van Biesen, W; Vanholder, R (June 2016). "The cell cycle biomarkers: promising research, but do not oversell them". Clinical Kidney Journal. 9 (3): 353–8. doi:10.1093/ckj/sfw033. PMC 4886923. PMID 27274818.